索托拉西布片（Sotorasib Tablets）

🧪 Ingredients

• Active ingredient: Sotorasib
• Dosage form: tablets
• Specifications: Provided as prescribed by a physician (common specification: 120 mg)

✅ Indications

• For the treatment of adult patients with **KRAS G12C mutation-positive locally advanced or metastatic non-small cell lung cancer (NSCLC)**.
• It is suitable for patients who have been confirmed to meet the treatment criteria through genetic testing.
• It helps inhibit tumor cell growth and slow disease progression.
• It can serve as an important component of personalized precision treatment plans.

💉 Usage and Dosage

Please take this product strictly according to your doctor’s prescription. The specific dosage and course of treatment should be adjusted based on the patient’s condition, genetic testing results, and treatment response. It is recommended to swallow the tablet whole, either with meals or on an empty stomach. Do not adjust the dosage or discontinue treatment on your own.

⚠️ Precautions

• Please use under the guidance of a professional doctor.
• It is recommended to monitor liver function, lung condition, and overall health status regularly during treatment .
• Please inform your doctor whether you have liver disease, lung disease, or other chronic diseases before taking this medication.
• If you experience persistent cough, difficulty breathing, jaundice, severe fatigue, or other unusual symptoms, seek medical attention promptly.

📦 Storage

Store in a cool, dry place, away from high temperatures, humidity, and direct sunlight. Keep in the original packaging and out of reach of children.

⭐ Summary

Sotorasib is an innovative targeted therapy for KRAS G12C mutation-positive tumors . By precisely inhibiting the KRAS G12C signaling pathway, it can effectively slow tumor progression, improve disease control rates, and provide a new treatment option for eligible patients. Please use it under the guidance of a professional physician and have regular follow-up and relevant examinations to achieve better treatment results.